Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haptoglobin-related protein (HPR) is a plasma protein encoded by the HPR gene in humans, closely related to haptoglobin (HP). It binds hemoglobin with high affinity, forming complexes distinct from those of haptoglobin, and acts as a component of trypanosome lytic factor-1 (TLF-1) along with apolipoprotein L1, mediating innate immune protection against African trypanosomes (agents of sleeping sickness). HPR does not facilitate clearance of hemoglobin via the CD163 receptor as haptoglobin does, meaning its hemoglobin complex persists longer in the plasma. Elevated levels of HPR or its gene copy number may be protective against trypanosome infection and could serve as a biomarker for breast cancer recurrence risk. No approved drugs directly target HPR, and no direct therapeutic safety concerns are documented. HPR is primarily considered an innate immune mediator, rather than a receptor, enzyme, or transporter.
No drug mechanisms targeting HPR directly, but HPR—through TLF-1—contributes to trypanosome lysis in innate immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Haptoglobin-related protein (HPR).